MK-677 (Ibutamoren) Legal Status and FDA Approval in 2026: The Complete Picture

MK-677 (ibutamoren mesylate) is in regulatory limbo. It is not FDA-approved, not a controlled substance, banned for athletes, removed from the compounding restriction list but awaiting formal review, and widely available as a research chemical that thousands of people are using without prescriptions.

To make sense of this, you need to understand four distinct regulatory frameworks that each treat MK-677 differently: FDA drug approval, DEA controlled substance scheduling, the FDA compounding pharmacy system, and WADA anti-doping rules. The answer to "is MK-677 legal?" depends entirely on which framework you are asking about.

FDA status: Not approved. MK-677 is classified as an Investigational New Drug. It has never completed the clinical trial process required for FDA approval. No pharmaceutical company currently holds an approved New Drug Application (NDA) for ibutamoren.

DEA status: Not scheduled. MK-677 is not listed in any DEA schedule (I through V). It is not classified as a controlled substance alongside steroids, narcotics, or stimulants. Possessing MK-677 is not a federal criminal offense under the Controlled Substances Act.

Compounding status: Under PCAC review. MK-677 was placed on the FDA Category 2 restricted list, which prohibits compounding pharmacies from manufacturing it. In April 2026, HHS Secretary Kennedy directed the FDA to remove all 12 remaining Category 2 peptides — including MK-677 — and refer them to the Pharmacy Compounding Advisory Committee for independent scientific evaluation. MK-677 is expected to be reviewed at a future PCAC meeting after the July 23–24 session.

WADA status: Prohibited at all times. MK-677 is on the WADA Prohibited List under category S2 as a growth hormone secretagogue.

MK-677 was originally developed by Merck Research Laboratories in the 1990s as a potential oral growth hormone secretagogue. The compound progressed through several clinical trials but was never brought to FDA approval. Understanding why illuminates the compound's risk-benefit profile.

Phase II trials. MK-677 was studied in multiple Phase II trials for conditions including growth hormone deficiency in the elderly, muscle wasting, hip fracture recovery, and osteoporosis. A 1998 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that oral MK-677 at 25 mg daily increased GH and IGF-1 levels to those of healthy young adults in elderly subjects. A 2-year study in elderly adults showed increased GH secretion and fat-free mass, though the effect on lean mass did not translate into significant functional improvements.

Why development stalled. Merck did not advance MK-677 to Phase III trials. While the specific reasons have not been publicly disclosed, the clinical data revealed several complicating factors: significant increases in fasting glucose and insulin resistance, fluid retention and edema (particularly concerning for elderly patients with cardiovascular risk), increased appetite leading to weight gain that offset metabolic benefits, and a signal for congestive heart failure in the elderly study population. These safety findings — particularly the cardiac risk in the target population of elderly patients with frailty — likely made the risk-benefit ratio unfavorable for FDA approval.

The patent situation. Merck's patents on MK-677 have expired, which means no pharmaceutical company has the financial incentive to invest the hundreds of millions of dollars required to complete Phase III trials and seek FDA approval for a compound they cannot exclusively market. This "orphan" status is a common situation for research chemicals that show promise but lack a commercial sponsor.

MK-677 is routinely marketed alongside SARMs (selective androgen receptor modulators) and grouped with them in online discussions. This misclassification has legal implications that users should understand.

What MK-677 actually is. MK-677 is a growth hormone secretagogue — a non-peptide agonist of the ghrelin receptor (GHSR). When it binds the ghrelin receptor in the hypothalamus and pituitary, it triggers the release of growth hormone. This is a completely different mechanism from SARMs, which bind androgen receptors to produce testosterone-like anabolic effects on muscle and bone.

Why the distinction matters legally. The SARMs Control Act (proposed in various forms since 2018) would classify SARMs as Schedule III controlled substances — the same category as anabolic steroids. If enacted, this would make unauthorized possession of SARMs a federal crime. However, because MK-677 is not a SARM and does not interact with androgen receptors, it would not be covered by SARMs-specific legislation. It would remain unscheduled even if a SARMs Control Act passes.

The marketing problem. Many online retailers sell MK-677 in "SARM stack" bundles and categorize it under their SARM product lines. This creates confusion for consumers and potentially for law enforcement. If you are purchasing MK-677, be aware that the retailer's product categorization does not reflect its actual pharmacological classification.

The most significant regulatory development for MK-677 in 2026 is its removal from the FDA Category 2 compounding restriction. Here is what that means and what comes next.

What happened. In April 2026, HHS Secretary Robert F. Kennedy Jr. directed the FDA to remove all 12 remaining peptides from the Category 2 restricted list and refer them to the Pharmacy Compounding Advisory Committee (PCAC) for scientific review. MK-677 (ibutamoren mesylate) was among these 12 substances.

What this means. Removal from Category 2 means MK-677 is no longer automatically excluded from compounding. However, it has not yet been added to the 503A bulk drug substances list (the "allowed" list for compounding). It is in a review state — the PCAC must evaluate the evidence and vote on whether to recommend inclusion.

The PCAC review timeline. The first PCAC meeting is scheduled for July 23–24, 2026, but that session will review BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax, and Epitalon. MK-677 is expected to be reviewed at a subsequent meeting that has not yet been scheduled. Based on the pace of regulatory action, this could occur in late 2026 or early 2027.

What would change if approved for compounding. If the PCAC recommends and the FDA approves MK-677 for the 503A list, licensed compounding pharmacies would be able to legally manufacture ibutamoren for patients with valid physician prescriptions. This would move MK-677 from the gray market to a regulated pharmacy setting with quality controls, physician oversight, and standardized dosing — a significant improvement in patient safety regardless of one's view of the compound's efficacy.

MK-677 is prohibited for all athletes in WADA-tested sports. This is not a nuanced or conditional prohibition — it is absolute.

Classification. WADA lists MK-677 under category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. Specifically, it falls under S2.4 as a growth hormone secretagogue. The prohibition applies at all times — in-competition and out-of-competition. There is no therapeutic use exemption (TUE) pathway that would permit MK-677 use while competing.

Detection. Anti-doping laboratories can detect MK-677 and its metabolites in urine samples. The detection window extends well beyond the pharmacological half-life of the parent compound. Athletes should assume that any recent use of MK-677 is detectable.

Who is affected. The WADA prohibition covers Olympic and Paralympic athletes, professional athletes in sports that adopt the World Anti-Doping Code, NCAA athletes (the NCAA references the WADA list), and military personnel subject to anti-doping policies. Recreational athletes and gym-goers who do not compete in tested sports are not subject to WADA rules, though they should be aware of the safety considerations.

Contamination risk. The unregulated supplement and research chemical market creates a contamination risk. Third-party testing has detected MK-677 in products that did not list it as an ingredient. Athletes in tested sports should only use supplements certified by NSF Certified for Sport, Informed Sport, or BSCG (Banned Substances Control Group).

The FDA has flagged MK-677 as presenting significant safety risks. These concerns are based on the clinical trial data that accumulated during Merck's development program.

Fluid retention and cardiac risk. MK-677 increases growth hormone, which promotes sodium and water retention. In clinical trials, peripheral edema (swelling in the extremities) was a common adverse effect. More concerning, the 2-year elderly study observed an increase in congestive heart failure events in the MK-677 group. While the study was not powered to definitively establish a causal relationship, the signal was sufficient to raise a red flag. Individuals with existing cardiovascular disease, hypertension, or heart failure risk factors should consider this carefully.

Blood sugar and insulin resistance. MK-677 consistently elevated fasting glucose and decreased insulin sensitivity in clinical trials. In the 2-year elderly study, fasting blood glucose increased by approximately 0.3 mmol/L. For individuals who are prediabetic, diabetic, or insulin-resistant, MK-677 could worsen metabolic health. Regular monitoring of HbA1c and fasting glucose is essential for anyone using MK-677.

Increased appetite. Activation of the ghrelin receptor predictably increases appetite — this is a feature of the mechanism, not a side effect. For individuals using MK-677 for body composition goals, the appetite increase can be counterproductive. Some users gain unwanted fat mass because they cannot control the increased hunger drive.

Joint pain and carpal tunnel symptoms. Elevated GH and IGF-1 levels can cause joint discomfort, particularly in the wrists and hands (symptoms mimicking carpal tunnel syndrome). These effects are typically dose-dependent and reversible upon discontinuation.

Quality control in the gray market. Because MK-677 is primarily purchased as a research chemical, product quality varies enormously. Third-party analyses have found products that are under-dosed, contaminated with other substances, or contain no active compound at all. The unregulated market compounds the pharmacological risks with manufacturing quality risks.

Given the complex regulatory landscape, here is practical guidance for different situations.

If you are an athlete in a tested sport: Do not use MK-677. The WADA prohibition is absolute, the detection window is long, and the consequences of a positive test are severe. This applies regardless of whether MK-677 is eventually approved for compounding.

If you are considering MK-677 for health reasons: Wait for the PCAC review outcome. If MK-677 is added to the 503A list, you will be able to obtain it from a licensed compounding pharmacy with a prescription — with quality assurance, physician oversight, and proper dosing. The risk of purchasing gray-market research chemicals is not justified when a regulated pathway may become available within months.

If you are currently using MK-677 from a research chemical source: Understand that you are using a product with no quality guarantee, no physician oversight of your specific medical situation, and known safety risks including cardiac and metabolic effects. At minimum, you should have baseline and periodic blood work including fasting glucose, HbA1c, IGF-1, and a basic metabolic panel. Report any edema, shortness of breath, or joint pain to a physician.

If you are a physician being asked about MK-677: The compound has legitimate Phase II data showing GH and IGF-1 effects, but the safety profile — particularly the cardiac and metabolic signals — makes it unsuitable for unsupervised use. If the PCAC approves it for compounding, it would be appropriate for carefully selected patients with monitoring. Until then, FDA-approved alternatives like tesamorelin (for GH-related indications) or other GH secretagogues should be considered.